Nicolas Martz

Radiation oncologist. Generally excited by #radonc ☢️

[Pierre Blanchard, MD @PBlanchardMD]

STOPCAP at #ESMO26

Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS.

Restricted to <5 bone or low volume mets on conventional imaging.

No interaction with other patient/tumor characteristics.

[Pierre Blanchard, MD @PBlanchardMD]

Another proof that metastasis directed therapy improves outcomes, this time in castration resistant #prostatecancer

Congrats to the PCS IX team!

author link at @TheLancetOncol: https://t.co/SLt68cCuQP

[Jonas Willmann, MD @jonas_willmann]

Distant failure after SBRT for oligometastatic disease is a common pattern of progression.
Yet, we lack validated post-progression models to guide treatment.
We tested whether Distant Metastasis Velocity (DMV) can fill this gap - and validated it across multinational cohorts 🧵

[Paul Sargos @PaulSargos]

🎗️Congrats to @NicolasDemogeot for this achievement.
✨ @GETUG_14, just published in
@EUplatinum

🔵 Phase III
🔵 376 pts (high risk and intermediate risk): high-dose RT versus STADT-RT
🔵'' High'' dose = 80 Gy
🔵 ADT decreased BF and MF but not OS

https://t.co/XXRM9jHM5T

[Jonas Willmann, MD @jonas_willmann]

❓ESTRO & EORTC proposed a classification to standardize reirradiation. But does it predict outcomes or toxicity?

🫁☢️ We applied the classification in thoracic reirradiation for NSCLC.

Here’s what we found.
🧵

[Paul Sargos @PaulSargos]

So happy to open this #ESTRO25 with the first edition of a pre meeting course on bladder cancer management with @achoud72
🔥@Achard_Verane

[Shankar Siva @_ShankarSiva]

1/ 🧨 OMET trial (GORTEC 2014-04) in oligometastatic HNSCC
👥 N=69, SABR alone vs SABR + chemo + cetuximab
🧪 Key finding: Similar 1-year OS without ⬇️QoL (SABR 55.2% vs chemo-SABR 53.3%).
🏆SABR alone had⬇️toxicity and QoL impact.
📉 Gr 3–4 tox: 8.8% (SABR alone) vs 60%
🧵

[IJROBP - The Red Journal @IJROBP]

1/6 We selected five Editor's Choice articles from the last several months, based on importance to the multidisciplinary oncology community - all free to read.
https://t.co/0BRRhV9dXQ

[JAMA Oncology @JAMAOnc]

In men diagnosed with GG1 prostate cancer undergoing active surveillance, higher adherence to American dietary guideline recommendations may be associated with a lower risk of grade reclassification. https://t.co/5u3ao6YM5z

[Matthias Guckenberger @Mat_Guc]

Aiming to refine your #radonc in 2025 !

Offer RT for low-volume metastatic PC pts, only ?
What benefit of RT is to be communicated ?
How about SBRT or surgery ?

Virtual Grand Rounds in Radiation Oncology

Jan 8th / 17:00 - 17:30 CET
Dr Alberto Bossi

👇
https://t.co/VMPm8mqf0R

[Jeff Ryckman @jryckman3]

🎉 Excited to share our latest work: RadOncCalc – A Mobile-Friendly Tool to Enhance Radiation Oncology Practice 📱⚛️

How does RadOncCalc help radiation oncologists save time and enhance patient care? Let’s break it down in this Tweetorial!

https://t.co/i1ooN43w7v

🧵👇

[Shankar Siva @_ShankarSiva]

📣@whallradonc presents phase II trial of dose escalated RT and elective nodes in VERY high risk #prostatecancer.
➡️10-year med. F/U
➡️>25% risk of clinical nodal involvement.
➡️outstanding 96% 10-year freedom from distant Mets
💥Hallelujah!
#pcsm #ASTRO24

[Paul Sargos @PaulSargos]

To be presented during ASTRO 2025 🇺🇸
@NicolasDemogeot
@stephane_supiot
@jnt_khalifa
@HennequinChris6
@AzrDavid
@GETUG_Unicancer
https://t.co/rcLbQz8rLi

[Pierre Blanchard, MD @PBlanchardMD]

Congrats to my friend @YG_TAO & GORTEC for this huge trial of IO in LA HNSCC

Avelumab-cetuximab inferior to cisplatin CRT in fit patients but superior to cetuximab-RT for PFS in cisplatin ineligible population.

#ESMO2024

[JAMA Oncology @JAMAOnc]

In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with high-risk biochemically recurrent prostate cancer following prostatectomy. https://t.co/bnNEUS2ZSv

[Asad Naveed @dr_asadnaveed]

How to write a strong discussion section: ⬇️

[The Lancet Oncology @TheLancetOncol]

Online First:

Adaptive #radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell #lungcancer, according to [18F]FDG-PET uptake (RTEP7–IFCT-1402): a multicentre, randomised, controlled, phase 2 trial

https://t.co/nLnDsIzY8c

[Matthias Guckenberger @Mat_Guc]

Virtual Grand Rounds in Radiation Oncology

Potentially Radiation-Oncology changing clinical trials from ASCO Annual Meeting 2024

Critical appraisal
from Radiation Oncologists
for Radiation Oncologists

Wednesday July 3rd 5:00 – 5:30 p.m.

https://t.co/VMPm8mpHbj

[Paul Sargos @PaulSargos]

CARLHA Phase II trial @stephane_supiot
In @EurUrolOncol
👑 Salvage RT + sTADT + Abi :
- 3-yr bRFS = 81.5%
- most common late AE (all grades) was urinary incontinence (15.2%)
- 11% pts had a CTC count of ≥5, correlated with poorer bRFS (p = 0.042)

https://t.co/SqcvRFJBNi

[ESTRO @ESTRO_RT]

Dose-escalated simultaneous integrated boost #radiotherapy in early #breastcancer (IMPORT HIGH): a multicentre phase 3 non-inferiority, open-label randomised controlled trial, published in @TheLancet
👉Read it before your patients: https://t.co/VCFWaO48xF
#ESTRONewsletter #radonc